ArticlePloS one2023
The macroeconomic burden of noncommunicable diseases and mental health conditions in South America.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Essential Medicines Availability, Pricing, and Stock-Outs for Hypertension and Diabetes in Private Retail Pharmacies in Zimbabwe.International journal of environmental research and public health · 2026Article
- HEARTS quality: a policy framework to strengthen hypertension and cardiovascular risk management in primary healthcare-insights from HEARTS in the Americas.Lancet regional health. Americas · 2026Review
- [HEARTS quality: a policy framework to strengthen hypertension and cardiovascular risk management in primary healthcare - insights from HEARTS in the AmericasQualidade da iniciativa HEARTS: marco de políticas para fortalecer o manejo da hipertensão e do risco cardiovascular na atenção primária à saúde. Perspectivas da iniciativa HEARTS nas Américas].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Trends and Association of Environmental Exposure and Climate Change with Non-Communicable Diseases in Latin America.Healthcare (Basel, Switzerland) · 2025Article
- Estimation and prediction on the economic burden of schistosomiasis in 25 endemic countries.Infectious diseases of poverty · 2025Article
- Investing in Addressing NCDs and Mental Health Conditions: a Political Choice.Annals of global health · 2025Article
- Editorial: Macroeconomic impact of disease dynamics: a temporal-spatial analysis.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noncommunicable diseases and mental health conditions (referred to collectively as NMHs) are the greatest cause of preventable death, illness, and disability in South America and negatively affect countries' economic performance through their detrimental impacts on labor supply and capital investments. Sound, evidence-based policy-making requires a deep understanding of the macroeconomic costs of NMHs and of their distribution across countries and diseases. The paper estimates and projects the macroeconomic burden of NMHs over the period 2020-2050 in 10 South American countries. We estimate the impact of NMHs on gross domestic product (GDP) through a human capital-augmented production function approach, accounting for mortality and morbidity effects of NMHs on labor supply, for the impact of treatment costs on physical capital accumulation, and for variations in human capital by age. Our central estimates suggest that the overall burden of NMHs in these countries amounts to $7.3 trillion (2022 international $, 3% discount rate, 95% confidence interval: $6.8-$7.8 trillion). Overall, the macroeconomic burden of NMHs is around 4% of total GDP over 2020-2050, with little variation across countries (from 3.2% in Peru to 4.5% in Brazil). In other words, without NMHs, annual GDP over 2020-2050 would be about 4% larger. In most countries, the largest macroeconomic burden is associated with cancers. Results from the paper point to a significant macroeconomic burden of NMHs in South America and provide a strong justification for investment in NMH prevention, early detection, treatment, and formal and informal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.